A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
Hummingbird Bioscience
Hummingbird Bioscience
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
Fate Therapeutics
Alterome Therapeutics, Inc.
Verastem, Inc.
Revolution Medicines, Inc.
Pfizer
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
BeOne Medicines
Incyte Corporation
Pfizer
Tizona Therapeutics, Inc
Revolution Medicines, Inc.
PAQ Therapeutics, Inc.
Eli Lilly and Company
Servier
Eli Lilly and Company
Innovent Biologics (Suzhou) Co. Ltd.